Subscribe to RSS
DOI: 10.3413/Nukmed-0568-13-03
Focal thyroid incidental uptake detected by 18F-fluorodeoxyglucose positron emission tomography
Meta-analysis on prevalence and malignancy riskInzidenteller fokaler Schilddrüsen-Uptake in der 18F-Flourdesoxyglukose-Positronenemissions tomographieMetaanalyse zu Prävalenz und Malignitäts risikoPublication History
received:
10 March 2013
accepted in revised form:
08 June 2013
Publication Date:
30 December 2017 (online)
![](https://www.thieme-connect.de/media/10.1055-s-00034924/201304/lookinside/thumbnails/10-3413-nukmed-0568-13-03_de-1.jpg)
Summary
Aim: To perform a meta-analysis of published data on the prevalence and risk of malignancy of focal thyroid incidental uptake (FTIs) detected by Fluorine-18-Fluorodeoxyglucose (18F-FDG) positron emission tomography (PET) or PET/CT. Methods: A comprehensive literature search of studies published up to and including December 2012 was performed. Pooled prevalence and malignancy risk of FTIs were calculated, including a sub-analysis for the geographic areas of origin of the studies. Results: 34 studies including 215 057 patients were selected. Pooled prevalence of FTIs was 1.92% (95% confidence interval [95%CI]: 1.87–1.99%). Overall, 1522 FTIs underwent histopathology evaluation. Pooled risk of malignancy was 36.2% (95%CI: 33.8–38.6%), without significant differences among various geographic areas. Conclusions: FTIs are observed in about 2% of 18F-FDG-PET or PET/CT scans and carry a significant risk of malignancy. Therefore, further investigation is warranted whenever FTIs are detected by 18F-FDG-PET or PET/CT.
Zusammenfassung
Ziel: Durchführen einer Meta-Analyse der publizierten Daten bezüglich der Prävalenz und des Malignitätsrisikos der inzidentellen fokalen Aufnahme in der Schilddrüse (FTI) in Fluor-18-Fluordeoxyglukose Positronenemissionstomographie oder PET/CT. Methoden: Eine umfassende Recherche der Literatur bis einschließlich 2012 auf entsprechende Studien wurde durchgeführt. Die gepoolte Prävalenz und das Malignitätsrisiko von FTI wurden berechnet, inklusive einer Subanalyse nach geographischer Herkunft der Studien. Ergebnisse: 34 Studien mit 215 057 Patienten wurden selektiert. Gepoolte Prävalenz von FTI war 1.92% (95% Zuverlässigkeitsintervall (95% CI): 1.87–1.99%). Davon wurden insgesamt 1522 FTI histopathologisch evaluiert. Das gepoolte Malignitätsrisiko betrug 36.2%, ohne signifikante Unterschiede zwischen verschiedenen geographischen Herkunftsgebieten. Schlussfolgerung: FTI werden in ungefähr 2% von 18F-FDG-PET oder PET/CT Scans beschrieben und gehen mit einem signifikanten Malignitätsrisiko einher. Daher ist eine weitere Abklärung erforderlich, falls ein FTI im 18F-FDG-PET oder PET/CT beschrieben wird.
-
References
- 1 Al-Hakami HA, Makis W, Anand S. et al. Head and neck incidentalomas on positron emission tomographic scanning: ignore or investigate?. J Otolaryngol Head Neck Surg 2011; 40: 384-390.
- 2 Are C, Hsu JF, Ghossein RA. et al. Histological aggressiveness of fluorodeoxyglucose positronemission tomogram (FDG-PET)-detected incidental thyroid carcinomas. Ann Surg Oncol 2007; 14: 3210-3215.
- 3 Are C, Hsu JF, Schoder H. et al. FDG-PET detected thyroid incidentalomas: need for further investigation?. Ann Surg Oncol 2007; 14: 239-247.
- 4 Bae JS, Chae BJ, Park WC. et al. Incidental thyroid lesions detected by FDG-PET/CT: prevalence and risk of thyroid cancer. World J Surg Oncol 2010; 7: 63.
- 5 Bertagna F, Treglia G, Piccardo A. et al. 18F-FDG-PET/CT thyroid incidentalomas: a wide retrospective analysis in three Italian centres on the significance of focal uptake and SUV value. Endocrine. 2012 DOI: 10.1007/s12020–012-9837-2
- 6 Boeckmann J, Bartel T, Siegel E. et al. Can the pathology of a thyroid nodule be determined by positron emission tomography uptake?. Otolaryngol Head Neck Surg 2012; 146: 906-912.
- 7 Bogsrud TV, Karantanis D, Nathan MA. et al. The value of quantifying 18F-FDG uptake in thyroid nodules found incidentally on whole-body PET-CT. Nucl Med Commun 2007; 28: 373-381.
- 8 Bonabi S, Schmidt F, Broglie MA. et al. Thyroid incidentalomas in FDG-PET/CT: prevalence and clinical impact. Eur. Arch. Otorhinolaryngol 2012; 269: 2555-2560.
- 9 Bongiovanni M, Spitale A, Faquin WC. et al. The Bethesda system for reporting thyroid cytopathology: a meta-analysis. Acta Cytol 2012; 56: 333-339.
- 10 Chen W, Parsons M, Torigian DA. et al. Evaluation of thyroid FDG uptake incidentally identified on FDG-PET/CT imaging. Nucl Med Commun 2009; 30: 240-244.
- 11 Chen YK, Ding HJ, Chen KT. et al. Prevalence and risk of cancer of focal thyroid incidentaloma identified by 18F-fluorodeoxyglucose positron emission tomography for cancer screening in healthy subjects. Anticancer Res 2005; 25: 1421-1426.
- 12 Choi JY, Lee KS, Kim HJ. et al. Focal thyroid lesions incidentally identified by integrated 18F-FDG PET/CT: clinical significance and improved characterization. J Nucl Med 2006; 47: 609-615.
- 13 Chu QD, Connor MS, Lilien DL. et al. Positron emission tomography (PET) positive thyroid incidentaloma: the risk of malignancy observed in a tertiary referral center. Am Surg 2006; 72: 272-275.
- 14 Cohen MS, Arslan N, Dehdashti F. et al. Risk of malignancy in thyroid incidentalomas identified by fluorodeoxyglucose-positron emission tomography. Surgery 2001; 130: 941-946.
- 15 Czepczyñski R, Stangierski A, Oleksa R. et al. Incidental 18F-FDG uptake in the thyroid in patients diagnosed with PET/CT for other malignancies. Nucl Med Rev Cent East Eur 2011; 14: 68-72.
- 16 Eloy JA, Brett EM, Fatterpekar GM. et al. The significance and management of incidental [18F]fluorodeoxyglucose-positron-emission tomography uptake in the thyroid gland in patients with cancer. AJNR Am J Neuroradiol 2009; 30: 1431-1434.
- 17 Even-Sapir E, Lerman H, Gutman M. et al. The presentation of malignant tumours and pre-malignant lesions incidentally found on PET-CT. Eur J Nucl Med Mol Imaging 2006; 33: 541-552.
- 18 Ho TY, Liou MJ, Lin KJ. et al. Prevalence and significance of thyroid uptake detected by 18F-FDG PET. Endocrine 2011; 40: 297-302.
- 19 Horvath E, Majlis S, Rossi R. et al. An ultrasonogram reporting system for thyroid nodules stratifying cancer risk for clinical management. J Clin Endocrinol Metab 2009; 94: 1748-1751.
- 20 Hsieh HJ, Lin SH, Yang BH. et al. The clinical relevance of thyroid incidentalomas detected by 18F-fluorodeoxyglucose positron emission tomography. Ann Nucl Med Sci 2003; 16: 53-58.
- 21 Ishimori T, Patel PV, Wahl RL. Detection of unexpected additional primary malignancies with PET/ CT. J Nucl Med 2005; 46: 752-757.
- 22 Jin J, McHenry CR. Thyroid incidentaloma. Best Pract Res Clin Endocrinol Metab 2012; 26: 83-96.
- 23 Kang BJ O JH, Baik JH. et al. Incidental thyroid uptake on 18F FDG PET/CT: correlation with ultrasonography and pathology. Ann Nucl Med 2009; 23: 729-737.
- 24 Kang KW, Kim SK, Kang HS. et al. Prevalence and risk of cancer of focal thyroid incidentaloma identified by 18F-fluorodeoxyglucose positron emission tomography for metastasis evaluation and cancer screening in healthy subjects. J Clin Endocrinol Metab 2003; 88: 4100-4104.
- 25 Kao YH, Lim SS, Ong SC. et al. Thyroid incidentalomas on fluorine-18-fluorodeoxyglucose positron emission tomography-computed tomography: Incidence, malignancy risk, and comparison of standardized uptake values. Can Assoc Radiol J 2012; 63: 289-293.
- 26 Karantanis D, Bogsrud TV, Wiseman GA. et al. Clinical significance of diffusely increased 18F-FDG uptake in the thyroid gland. J Nucl Med 2007; 48: 896-901.
- 27 Kim BH, Kim IJ, Kim SS. et al. Relationship between biological marker expression and fluorine-18 fluorodeoxyglucose uptake in incidentally detected thyroid cancer. Cancer Biother Radiopharm 2010; 25: 309-315.
- 28 Kim BH, Na MA, Kim IJ. et al. Risk stratification and prediction of cancer of focal thyroid fluorodeoxyglucose uptake during cancer evaluation. Ann Nucl Med 2010; 24: 721-728.
- 29 Kim TY, Kim WB, Ryu JS. et al. 18F-fluorodeoxyglucose uptake in thyroid from positron emission tomogram (PET) for evaluation in cancer patients: high prevalence of malignancy in thyroid PET incidentaloma. Laryngoscope 2005; 115: 1074-1078.
- 30 King DL, Stack Jr BC, Spring PM. et al. Incidence of thyroid carcinoma in fluorodeoxyglucose positron emission tomography-positive thyroid incidentalomas. Otolaryngol Head Neck Surg 2007; 137: 400-404.
- 31 Lee WM, Kim BJ, Kim MH. et al. Characteristics of thyroid incidentalomas detected by pre-treatment [F]FDG PET or PET/CT in patients with cervical cancer. J Gynecol Oncol 2012; 23: 43-47.
- 32 Lin M, Wong C, Lin P. et al. The prevalence and clinical significance of 18F-2-fluoro-2-deoxy-D-glucose (FDG) uptake in the thyroid gland on PET or PET-CT in patients with lymphoma. Hematol Oncol 2011; 29: 67-74.
- 33 Nam SY, Roh JL, Kim JS. et al. Focal uptake of 18F-fluorodeoxyglucose by thyroid in patients with nonthyroidal head and neck cancers. Clin Endocrinol 2007; 67: 135-139.
- 34 Nilsson IL, Arnberg F, Zedenius J. et al. Thyroid incidentaloma detected by fluorodeoxyglucose positron emission tomography/computed tomography: practical management algorithm. World J Surg 2011; 35: 2691-2697.
- 35 Nishimori H, Tabah R, Hickeson M. et al. Incidental thyroid „PETomas“: clinical significance and novel description of the self-resolving variant of focal FDG-PET thyroid uptake. Can J Surg 2011; 54: 83-88.
- 36 Ohba K, Nishizawa S, Matsushita A. et al. High incidence of thyroid cancer in focal thyroid incidentaloma detected by 18F-fluorodeoxyglucose [corrected] positron emission tomography in relatively young healthy subjects: results of 3-year follow-up. Endocr J 2010; 57: 395-401.
- 37 Pagano L, Samà MT, Morani F. et al. Thyroid incidentaloma identified by 18F-fluorodeoxyglucose positron emission tomography with CT (FDG PET/CT): clinical and pathological relevance. Clin Endocrinol 2011; 75: 528-534.
- 38 Pampaloni MH, Win AZ. Prevalence and characteristics of incidentalomas discovered by whole body FDG PETCT. Int J Mol Imaging 2012; 2012: 476763.
- 39 Prichard RS, Cotter M, Evoy D. et al. Focal thyroid incidentalomas identified with whole-body FDG-PET warrant further investigation. Ir Med J 2011; 104: 177-179.
- 40 Salvatori M, Melis L, Castaldi P. et al. Clinical significance of focal and diffuse thyroid diseases identified by 18F-fluorodeoxyglucose positron emission tomography. Biomed Pharmacother 2007; 61: 488-493.
- 41 Soelberg KK, Bonnema SJ, Brix TH. et al. Risk of malignancy in thyroid incidentalomas detected by 18F-fluorodeoxyglucose positron emission tomography: a systematic review. Thyroid 2012; 22: 918-925.
- 42 Stack Jr BC, Bodenner DL, Bartel TB, Boeckmann J. Focal thyroid uptake on 18F-fluorodeoxyglucose positron emission tomography: interpreting the data. Thyroid 2013; 23: 636-637.
- 43 Treglia G, Giovanella L, Bertagna F. et al. A pooled analysis to calculate the prevalence and risk of malignancy of thyroid incidentalomas detected by fluorine-18-fluorodeoxyglucose positron emission tomography. Thyroid. 2012 DOI: 10.1089/thy.2012–0216
- 44 Treglia G, Sadeghi R. Meta-analyses and systematic reviews on PET and PET/CT in oncology: the state of the art. Clin Transl Imaging 2013; 1: 73-75.
- 45 WHO Nutrition. The WHO Global Database on Iodine Deficiency. www.who.int/vmnis/en/ (accessed January 30th 2013).
- 46 Wong C, Lin M, Chicco A. et al. The clinical significance and management of incidental focal FDG uptake in the thyroid gland on positron emission tomography/computed tomography (PET/CT) in patients with non-thyroidal malignancy. Acta Radiol 2011; 52: 899-904.
- 47 Yang Z, Shi W, Zhu B. et al. Prevalence and risk of cancer of thyroid incidentaloma identified by fluorine-18 fluorodeoxyglucose positron emission tomography/computed tomography. J Otolaryngol Head Neck Surg 2012; 41: 327-333.
- 48 Yi JG, Marom EM, Munden RF. et al. Focal uptake of fluorodeoxyglucose by the thyroid in patients undergoing initial disease staging with combined PET/CT for non-small cell lung cancer. Radiology 2005; 236: 271-275.
- 49 Zhai G, Zhang M, Xu H. et al. The role of 18F-fluorodeoxyglucose positron emission tomography/computed tomography whole body imaging in the evaluation of focal thyroid incidentaloma. J Endocrinol Invest 2010; 33: 151-155.